Gates MA, Holowka DW, Vasterling JJ, Keane TM, Marx BP, Rosen RC. Posttraumatic stress disorder in veterans and military personnel: epidemiology, screening, and case recognition. Psychol Serv. 2012 Nov;9(4):361–82.
Koek RJ, Schwartz HN, Scully S, Langevin JP, Spangler S, Korotinsky A, et al. Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;70:170–218.
Thomas JL, Wilk JE, Riviere LA, McGurk D, Castro CA, Hoge CW. Prevalence of mental health problems and functional impairment among active component and National Guard soldiers 3 and 12 months following combat in Iraq. Arch Gen Psychiatry. 2010;67(6):614–23.
URL https://www.healthquality.va.gov/guidelines/mh/ptsd/index.asp Website Title Management of Posttraumatic Stress Disorder and Acute Stress Reaction 2017 - VA/DoD Clinical Practice Guidelines Article Title VA/DoD clinical practice guidelines Date Published June 2017. Date Accessed 26 Mar 2018.
URL https://clinicaltrials.gov/ Website Title Home - ClinicalTrials.gov. Date Accessed 26 Mar 2018.
American Psychological Association. Clinical practice guidelines for the treatment of PTSD. 2017 February 24.
Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive compulsive disorder: a revision of the 2005 guidelines from British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–39.
URL http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001769 Website Title PLOS Medicine Article Title World Health Organization guidelines for management of acute stress, ptsd, and bereavement: key challenges on the road ahead Date Published December 2014. Date Accessed 26 June 2018.
URL https://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-14-S1-S1 Website Title BMC Psychiatry Article Title Canadian clinical practice guidelines for management of anxiety, posttraumatic stress and obsessive-compulsive disorders Date Published 2014. Date Accessed 26 June 2018.
Kline AC, Cooper AA, Rytwinksi NK, Feeny NC. Long-term efficacy of psychotherapy for posttraumatic stress disorder: a meta-analysis of randomized controlled trials. Clin Psychol Rev. 2017.
Lu MW, Duckart JP, O’Malley JP, Dobscha SK. Correlates of utilization of PTSD specialty treatment among recently diagnosed veterans at the VA. Psychiatr Serv. 2011;62(8):943–9.
Thomas E, Stein DJ. Novel pharmacological treatment strategies for posttraumatic stress disorder. Expert Rev Clin Pharmacol. 2017;10(2):167–77.
Kelmendi B, Adams TG, Yarnell S, Southwick S, Abdallah CG, Krystal JH. PTSD: from neurobiology to pharmacological treatments. Eur J Psychotraumatol. 2016;7(1):31858.
Krystal JH, Davis LL, Neylan TC, Raskind MA, Schnurr PP, Stein MB, et al. It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD psychopharmacology working group. Biol Psychiatry. 2017;82(7):e51–9.
Raskind MA, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, et al. Trial of prazosin for post-traumatic stress disorder in military veterans. N Engl J Med. 2018;378(6):507–17.
Raskind MA, Millard SP, Petrie EC, Peterson K, Williams T, Hoff DJ, et al. Higher pretreatment blood pressure is associated with greater posttraumatic stress disorder symptom reduction in soldiers treated with prazosin. Biol Psychiatry. 2016;80(10):736–42.
Richards A, Inslicht S, Ruoff LM, Metzler TJ, Goldstein LA, Chapman CM, et al. An open-label study of doxazosin extended-release for PTSD: findings and recommendations for future research on doxazosin. Focus. 2018;16(1):67–73.
Rodgman C, Verrico CD, Holst M, Thompson-Lake D, Haile CN, Raskind MA, et al. Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial. J Clin Psychiatry. 2016;77(5):e561–5.
• Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, Abdallah CG. Glutamate dysregulation and glutamatergic therapeutics for PTSD: evidence from human studies. Neurosci Lett. 2017;649:147–55. Glutamate dysregulation can lead to synaptic dysconnectivity and dysregulation of fear and emotion circuits.
URL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020599s011s012lbl.pdf. Date Accessed 26 Mar 2018.
• Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, et al. Synaptic loss and the pathophysiology of PTSD: implications for ketamine as a prototype novel therapeutic. Curr Psychiatry Rep. 2017;19(10):74. By reversing neuronal stress, ketamine may have quick benefits in PTSD, similar to its rapid antidepressant effects.
Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681–8.
Schwartz J, Murrough JW, Iosifescu DV. Ketamine for treatment-resistant depression: recent developments and clinical applications. Evid Based Ment Health. 2016;19(2):35–8.
Back SE, McCauley JL, Korte KJ, Gros DF, Leavitt V, Gray KM, et al. A double-blind randomized controlled pilot trial of n-acetylcysteine in veterans with PTSD and substance use disorders. J Clin Psychiatry. 2016;77(11):e1439.
• Rasmusson AM, Marx CE, Pineles SL, Locci A, Scioli-Salter ER, Nillni YI, et al. Neuroactive steroids and PTSD treatment. Neurosci Lett. 2017;649:156–63. Glucocorticoids, 17β-estradiol, and GABAergic neuroactive steroids regulate the fear pathway and facilitate fear extinction.
Rasmusson AM, Marx CE, Jain S, Farfel GM, Tsai J, Sun X, et al. A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology. 2017;234(15):2245–57.
• Kautz M, Charney DS, Murrough JW. Neuropeptide Y, resilience, and PTSD therapeutics. Neurosci Lett. 2017;649:164–9. NPY modulates stress and anxiety responses through its actions via NPY 1 and 2 receptors.
Sayed S, Van Dam NT, Horn SR, Kautz MM, Parides M, Costi S, et al. A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder. Int J Neuropsychopharmacol. 2017 Nov 23;21(1):3–11.
Sack M, Spieler D, Wizelman L, Epple G, Stich J, Zaba M, et al. Intranasal oxytocin reduces provoked symptoms in female patients with posttraumatic stress disorder despite exerting sympathomimetic and positive chronotropic effects in a randomized controlled trial. BMC Med. 2017 Dec;15(1):40.
Nawijn L, van Zuiden M, Koch SB, Frijling JL, Veltman DJ, Olff M. Intranasal oxytocin increases neural responses to social reward in post-traumatic stress disorder. Soc Cogn Affect Neurosci. 2016;12(2):212–23.
Koch SB, van Zuiden M, Nawijn L, Frijling JL, Veltman DJ, Olff M. Intranasal oxytocin normalizes amygdala functional connectivity in posttraumatic stress disorder. Neuropsychopharmacology. 2016;41(8):2041–51.
van Zuiden M, Frijling JL, Nawijn L, Koch SB, Goslings JC, Luitse JS, et al. Intranasal oxytocin to prevent posttraumatic stress disorder symptoms: a randomized controlled trial in emergency department patients. Biol Psychiatry. 2017;81(12):1030–40.
Mendoza C, Barreto GE, Iarkov A, Tarasov VV, Aliev G, Echeverria V. Cotinine: a therapy for memory extinction in post-traumatic stress disorder. Mol Neurobiol. 2018;15:1–2.
URL www.bionomics.com.au/upload/research-development/poster-presentations-publications/cns-poster-presentations/2017-10-SO-BNC210-A-Novel-Therapeutic_1.pdf. Date Accessed 26 Mar 2018.
Sessa B. MDMA and PTSD treatment: “PTSD: from novel pathophysiology to innovative therapeutics”. Neurosci Lett. 2017 May 10;649:176–80.
URL https://www.tonixpharma.com/research-development/tonmya-for-ptsd Website TitleTonix Pharmaceuticals Holding Corp. (TNXP) Article TitleTonmya for PTSD. Date Accessed 26 Mar 2018 32.
• Loflin MJ, Babson KA, Bonn-Miller MO. Cannabinoids as therapeutic for PTSD. Curr Opin Psychology. 2017;14:78–83. Cannabinoids have potential to reduce cue-elicited fear, block reconsolidation of fear memories, and facilitate extinction of this.
Peterson K, Bourne D, Anderson J, Mackey K, Helfand M. Evidence brief: effectiveness of stellate ganglion block for treatment of posttraumatic stress disorder (PTSD).
Kozel FA, Motes MA, Didehbani N, DeLaRosa B, Bass C, Schraufnagel CD, et al. Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD: a randomized clinical trial. J Affect Disord. 2018;229:506–14.
Lavano A, Guzzi G, Della Torre A, Lavano SM, Tiriolo R, Volpentesta G. DBS in treatment of post-traumatic stress disorder. Brain Sci. 2018;8(1):18.
• Mishkind MC, Norr AM, Katz AC, Reger GM. Review of virtual reality treatment in psychiatry: evidence versus current diffusion and use. Curr Psychiatry Rep. 2017;19(11):80. Computer-generated virtual systematic exposure therapy offers a unique treatment option.
McLay RN, Baird A, Webb-Murphy J, Deal W, Tran L, Anson H, et al. A randomized, head-to-head study of virtual reality exposure therapy for posttraumatic stress disorder. Cyberpsychol Behav Soc Netw. 2017;20(4):218–24.
Gallegos AM, Crean HF, Pigeon WR, Heffner KL. Meditation and yoga for posttraumatic stress disorder: a meta-analytic review of randomized controlled trials. Clin Psychol Rev. 2017;58:115–24.
• Madsen C, Vaughan M, Koehlmoos TP. Use of integrative medicine in the United States military health system. Evid Based Complement Alternat Med. 2017;2017. Patient driven demand for integrative medicine modalities.